Mr Bauer was previously chief executive officer at Neosil which was acquired by Peplin in 2008. He served as vice president for medical affairs and dean of the Stanford University School of Medicine from 1995 to 2001 and served as chair of the department of dermatology at the Stanford University School of Medicine from 1988 to 1995.
Haro Hartounian, president and chief executive officer of Vyteris, said: “Dr Bauer’s proven track record in building successful development-stage companies, combined with his extensive experience in directing clinical programs, will be invaluable as we revitalize our development efforts for our proprietary drug delivery technology. We welcome him to the Vyteris board and look forward to his contributions.”
Vyteris is the maker of ready-to-use drug delivery patch (LidoSite) to receive marketing clearance from the US FDA. Vyteris’ active transdermal smart patch technology delivers drugs through the skin using low-level electrical energy (iontophoresis).